Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | Q0244 |
Short Description | Casirivi and imdevi 1200 mg |
Long Description | Injection, casirivimab and imdevimab, 1200 mg |
Pricing indicator | 54 |
Coverage code | C |
ASC payment group code | |
BETOS2 code | O1G |
Action code | N |
Type of service | V |
Effective date | 2021-06-03 |
Date Added | 2021-06-03 |
Drug Details
-
Casirivimab and imdevimab injection is used in certain non-hospitalized adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) and who have certain medical conditions that make them at higher risk for developing severe COVID-19 symptoms, including hospitalization or death:
-
to treat mild to moderate symptoms of COVID-19.
-
to prevent COVID-19 in those who are not fully vaccinated against COVID-19 or who are vaccinated, but have a weakened immune system, or are taking a medication that affects the immune system and who have had close contact or are at high risk of close contact to someone who is infected with the SARS-CoV-2 virus (for example, nursing homes, prisons).
-
-
Casirivimab and imdevimab are in a class of medications called monoclonal antibodies. They work by blocking the action of a certain natural substance in the body in order to stop the spread of the virus.